Indications and Purposes
| 1 Indications And Usage Beleodaq Is Indicated For The Treatment Of Patients With Relapsed Or Refractory Peripheral T-Cell Lymphoma (Ptcl). This Indication Is Approved Under Accelerated Approval Based On Tumor Response Rate And Duration Of Response [See Clinical Studies ( 14 )]. An Improvement In Survival Or Disease-Related Symptoms Has Not Been Established. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In The Confirmatory Trial. Beleodaq Is A Histone Deacetylase Inhibitor Indicated For The Treatment Of Patients With Relapsed Or Refractory Peripheral T-Cell Lymphoma (Ptcl). This Indication Is Approved Under Accelerated Approval Based On Tumor Response Rate And Duration Of Response. An Improvement In Survival Or Disease-Related Symptoms Has Not Been Established. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In The Confirmatory Trial. (1) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Belinostat |
|
ZINC3818726 |